Hospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (65)

2024

  1. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank

    Clinical and experimental rheumatology, Vol. 42, Núm. 2, pp. 277-287

  2. Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: A post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial

    Journal of Bone and Mineral Research, Vol. 39, Núm. 10, pp. 1486-1492

  3. Quality of life of patients with rheumatic diseases

    Reumatologia Clinica, Vol. 20, Núm. 2, pp. 59-66

  4. Successful treatment of AA amyloidosis with tocilizumab, resulting in the disappearance of amyloid deposits: a case-based review

    Egyptian Rheumatology and Rehabilitation, Vol. 51, Núm. 1

  5. Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study

    JMIR Research Protocols, Vol. 13, Núm. 1

2023

  1. Evaluating remission and low disease activity from the perspective of the patient with axial spondyloarthritis: The cross-sectional ConREspAx study

    Joint Bone Spine, Vol. 90, Núm. 2

  2. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2615-2624

  3. Myositis autoantibodies detected by line blot immunoassay: clinical associations and correlation with antibody signal intensity

    Rheumatology International, Vol. 43, Núm. 6, pp. 1101-1109

  4. Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry

    Modern rheumatology, Vol. 34, Núm. 1, pp. 97-105

2022

  1. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies

    Clinical and experimental rheumatology, Vol. 40, Núm. 2, pp. 274-283

  2. Low Positivity Rate of Anti-SARS-CoV-2 IgG in Unvaccinated Patients With Rheumatic Diseases Treated With Rituximab

    Journal of Clinical Rheumatology, Vol. 28, Núm. 8, pp. 424-428

  3. Retention rate of secukinumab in psoriatic arthritis: Real-world data results from a Spanish multicenter cohort

    Medicine (United States), Vol. 101, Núm. 36, pp. E30444

2021

  1. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up

    Rheumatology (Oxford, England), Vol. 60, Núm. 6, pp. 2906-2915

  2. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases

    Pediatric Rheumatology, Vol. 19, Núm. 1

  3. Development of Iatrogenic Cushing Syndrome after Peri-articular Glucocorticoid Injection in an Human Immunodeficiency Virus Patient on Protease Inhibitor Therapy

    Journal of Clinical Rheumatology

  4. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 7, pp. 930-942

  5. Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis

    Frontiers in Medicine, Vol. 8

  6. Rheumatoid meningitis as a complication of long-standing rheumatoid arthritis: a case treated with rituximab

    Modern Rheumatology Case Reports, Vol. 5, Núm. 2, pp. 200-205

  7. Risk of severe COVID-19 infection in patients with inflammatory rheumatic diseases

    Journal of Rheumatology, Vol. 48, Núm. 7, pp. 1098-1102

2020

  1. Association of apolipoprotein B/apolipoprotein A1 ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study

    Clinical and experimental rheumatology, Vol. 38, Núm. 4, pp. 662-669